Narayan notes, "It is well recognised that not all currently available treatments are capable of controlling joint inflammation in all patients with rheumatoid arthritis, hence the need to develop new pharmacological therapies. This work demonstrates that TSPO PET is able to act as a means of imaging not only synovial macrophages, but also activated synovial fibroblasts. The crucial role of the fibroblast and its soluble products in RA pathogenesis is increasingly realised."
She adds, "Indeed, there has been recent interest in targeting activated fibroblasts as a novel targeted treatment strategy for RA. Therefore, TSPO PET imaging in early phase clinical trials may provide a sensitive indication of treatment response to such novel therapies with a view to informing the design of later stage clinical trials. As our knowledge of cellular TSPO expression and behavior grows, TSPO-targeted imaging may also give us unique insights into the pathogenesis of inflammatory disease."
Ad Statistics
Times Displayed: 46200
Times Visited: 1302 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Authors of "Translocator protein as an imaging marker of macrophage and stromal activation in RA pannus" include Nehal Narayan, Harpreet Mandhair, Francesco Carlucci, Stephanie G. Dakin, Afsie Sabokbar, and Peter C. Taylor, University of Oxford, Headington, Oxford, UK; David R. Owen, Imperial College, Hammersmith, London, UK; Erica Smyth, Azeem Saleem, Roger N. Gunn, and Lisa Wells, Imanova Centre for Imaging Sciences, Hammersmith, London, UK; and Eugenii A. Rabiner, Imanova Centre for Imaging Sciences, Hammersmith, London, and King's College, London, UK.
The research was supported by the National Institute for Health Research Oxford Biomedical Research Centre, an IMPETUS pilot study grant from Imanova, Academic Centre for Imaging Sciences, an MRC clinician scientist award (MR/N008219/1), and Arthritis Research UK (20506).
ABOUT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI's more than 15,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice.
Back to HCB News
